CC BY-NC-ND 4.0 · J Neuroanaesth Crit Care 2019; 06(02): 056-061
DOI: 10.1055/s-0039-1688897
Review Article
Indian Society of Neuroanaesthesiology and Critical Care

Sedation During Neurocritical Care

Nieves Vanaclocha
1   Department of Plastic Reconstructive Surgery, Hospital Universitario y Politécnico La Fe, Valencia, Spain
,
Vicente Chisbert
2   Escuela de Doctorado, Universidad Católica de Valencia, “San Vicente Mártir,” Spain
,
Vicent Quilis
3   Department of Neurosurgery, Hospital Clínic Universitari de València, Spain
4   College of Medicine and Science, Mayo Clinic, United States
5   Department of Human Anatomy and Embryology, Faculty of Medicine, University of Valencia, Spain
,
Federico Bilotta
6   Department of Anesthesiology, University of Rome “La Sapienza,” Rome, Italy
,
Rafael Badenes
7   Department of Anesthesiology and Surgical-Trauma Intensive Care, Hospital Clinic Universitari Valencia, University of Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received: 04 February 2019

Accepted: 18 March 2019

Publication Date:
06 June 2019 (online)

Zoom Image

Abstract

Sedation is an essential therapeutic strategy in the care of neurocritical patients. Intravenous sedative agents are the most widely used, with promising alternatives (dexmedetomidine, ketamine, and volatile agents) to propofol and midazolam arising. Studies designed to evaluate superiority and avoid biases are required. A neurological awakening test is safe in most patients. Potential risks and benefits of limiting deep sedation and daily interruption of sedation in these patients remain unclear. The aim of this review was to report recent clinical evidence on sedation in this subgroup of patients, focusing on its effects on clinical prognosis.